Neptune Technologies & Bioressources Inc. Receives Nutraceutical GMP Accreditation
Monday, March 06 2006

Neptune Technologies & Bioressources Inc. Receives Nutraceutical GMP Accreditation

Laval, Quebec, Canada, March 1st, 2006 - Neptune Technologies & Bioressources Inc., (TSX Venture Exchange: NTB), «Neptune» is pleased to announce that it has obtained a Site License issued by the Minister of Health, Health Canada, under the Authority of the section 22 of the Directorate of Natural Health Products Regulations.

Health Canada has established new regulations to ensure that Natural Health Products are consistently manufactured and controlled in such a way to meet the highest quality and safety standards appropriate to their intended use. Neptune has achieved a major milestone by implementing its Quality Assurance Program to Good Manufacturing Practices (GMP); a rigorous process where every step of Neptune’s manufacturing has been traced, verified, validated and accredited by Health Canada.

“It is a rigorous process to be GMP licensed and an instant recognition of the highest standards in the industry for Neptune’s production” said Mr. Alain Marchand, Chemical Engineer, Plant Manager at Neptune Technologies and Bioressources Inc. Sherbrooke, Quebec Plant. “Every step of Neptune manufacturing from raw material and ingredients to the packaging of the final product is performed under validated and accredited Standard Operating Procedures (SOP), in compliance with GMP requirements. “This accreditation will open new doors to the world market by meeting the highest expectations of Industry leaders who demand rigorous and validated manufacturing standards in order to assure the highest quality possible” added Mr. Marchand.

About Neptune Technologies & Bioressources Inc. https://www.neptunebiotech.com/
Neptune Technologies & Bioressources Inc. develops high value added nutritional products from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract™). Using an exclusive process, Neptune Technologies & Bioressources Inc. is well positioned in the $182 billion global nutrition market (Nutrition Business Journal, Oct/Nov 2004) of health and wellness concepts.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the adequacy or accuracy of this press release.
Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc.
Acasti Pharma Inc.
Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations
(450) 687-2262
This e-mail address is being protected from spambots, you need JavaScript enabled to view it
# # #
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
 

We communicate

NTB (TSX) CAN$ 1.93 +0.03
NEPT (NASDAQ) US$ 1.898 +0.068
 

press releases

Investor Relations Contact NEPTUNE TECHNOLOGIES & BIORESSOURCES